Ann Dermatol.  2015 Jun;27(3):298-305. 10.5021/ad.2015.27.3.298.

Economic Impact of Atopic Dermatitis in Korean Patients

• Kim C
• Park KY
• Ahn S
• Kim DH
• Li K
• Kim DW
• Kim MB
• Jo SJ
• Yim HW
• Seo SJ

• KMID: 2352501
• DOI: http://doi.org/10.5021/ad.2015.27.3.298

Abstract

BACKGROUND
Atopic dermatitis is a global public health concern owing to its increasing prevalence and socioeconomic burden. However, few studies have assessed the economic impact of atopic dermatitis in Korea.
OBJECTIVE
We conducted a cost analysis of atopic dermatitis and evaluated its economic impacts on individual annual disease burden, quality of life, and changes in medical expenses with respect to changes in health related-quality of life.
METHODS
The cost analysis of atopic dermatitis was performed by reviewing the home accounting records of 32 patients. The economic impact of the disease was evaluated by analyzing questionnaires. To handle uncertainties, we compared the results with the data released by the Health Insurance Review & Assessment Board on medical costs claimed by healthcare facilities.
RESULTS
The direct cost of atopic dermatitis per patient during the 3-month study period was 541,280 Korean won (KRW), and expenditures on other atopic dermatitis-related products were 120,313 KRW. The extrapolated annual direct cost (including expenditures on other atopic dermatitis-related products) per patient was 2,646,372 KRW. The estimated annual indirect cost was 1,507,068 KRW. Thus, the annual cost of illness of atopic dermatitis (i.e., direct+indirect costs) was estimated to be 4,153,440 KRW.
CONCLUSION
The annual total social cost of atopic dermatitis on a national level is estimated to be 5.8 trillion KRW.

Keyword

Atopic dermatitis; Cost analysis; Cost of illness; Economic evaluation; Quality of life

MeSH Terms

Cost of Illness
Costs and Cost Analysis
Delivery of Health Care
Dermatitis, Atopic*
Health Expenditures
Humans
Insurance, Health
Korea
Prevalence
Public Health
Quality of Life
Surveys and Questionnaires

Figure

• 

  Fig. 1 Kaplan-meier curve for EuroQol 5 Dimension, Korean version and total direct cost (linear regression analysis).

Reference

1. Yu JS, Lee CJ, Lee HS, Kim J, Han Y, Ahn K, et al. Prevalence of atopic dermatitis in Korea: analysis by using national statistics. J Korean Med Sci. 2012; 27:681–685.

2. Mancini AJ, Kaulback K, Chamlin SL. The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol. 2008; 25:1–6.

3. Kang E, Shin H, Park H, Jo M, Kim N. A validation of Health Status Using EQ-5D. Korean J Health Econ Policy. 2006; 12:19–43.

4. Kim CM. Health economics and outcomes research. Korean J Fam Med. 2009; 30:577–587.

5. Park MK, Park KY, Li K, Seo SJ, Hong CK. The short stature in atopic dermatitis patients: are atopic children really small for their age? Ann Dermatol. 2013; 25:23–27.

6. Ricci G, Bendandi B, Pagliara L, Patrizi A, Masi M. Atopic dermatitis in Italian children: evaluation of its economic impact. J Pediatr Health Care. 2006; 20:311–315.

7. Verboom P, Hakkaart-Van L, Sturkenboom M, De Zeeuw R, Menke H, Rutten F. The cost of atopic dermatitis in the Netherlands: an international comparison. Br J Dermatol. 2002; 147:716–724.

8. Gieler U, Hohmann M, Niemeier V, Kupfer J. Cost evaluation in atopic eczema. J Dermatolog Treat. 1999; 10:S15–S20.

9. Rathjen D, Thiele K, Staab D, Helberger C. Die Gesch ftsten Kosten Von Neurodermitis bei Kindern. Z Gezundheitswiss. 2000; 8:14–25.

10. Choi WJ, Ko JY, Kim JW, Lee KH, Park CW, Kim KH, et al. Prevalence and risk factors for atopic dermatitis: a cross-sectional study of 6,453 Korean preschool children. Acta Derm Venereol. 2012; 92:467–471.

11. Suh DC, Sung J, Gause D, Raut M, Huang J, Choi IS. Economic burden of atopic manifestations in patients with atopic dermatitis--analysis of administrative claims. J Manag Care Pharm. 2007; 13:778–789.